CASRAI Dictionary

Tag: biorxiv publisher

  • BioRxiv ISSN Explained: Why It’s Not a Journal

    BioRxiv holds ISSN 2692-8205, but an ISSN is a serial-registration number, not proof of peer review. BioRxiv is a preprint repository, not a peer-reviewed journal: it has no Scimago Journal Rank, no Scopus record and no impact factor, because those metrics apply only to indexed journals, and bioRxiv does not perform peer review.

    BioRxiv is an open-access preprint repository for the biological sciences, launched in November 2013 by John Inglis and Richard Sever and now operated by the nonprofit openRxiv. Confusion about its status is common because bioRxiv looks and behaves like a journal platform — it has a citable DOI, a formal ISSN and a Wikipedia entry — while lacking the editorial infrastructure that “indexing” actually measures.

    Does bioRxiv have an ISSN, and what does that prove?

    BioRxiv is registered with ISSN 2692-8205, listed in the ISSN Portal and cross-referenced in the NLM Catalog under record ID 101680187, where the U.S. National Library of Medicine lists its electronic ISSN and title abbreviation “bioRxiv: the preprint server for biology”. An ISSN is issued by the ISSN International Centre to any continuing resource — journals, newspapers, monograph series, and repositories that publish serially.

    Holding an ISSN confirms only that a publication is a recognised, ongoing serial with a stable identity. It carries no implication about peer review, editorial oversight, or scholarly indexing. Many predatory journals and informal newsletters also carry valid ISSNs, which is precisely why the number is frequently mistaken for a quality signal.

    Is bioRxiv indexed in Scimago or Scopus?

    No. Scimago Journal & Country Rank derives its rankings exclusively from the Scopus citation database, which indexes peer-reviewed journals, conference proceedings and book series — not preprint servers. Because bioRxiv preprints are not peer-reviewed at the point of posting, they fall outside Scopus’s inclusion criteria, and bioRxiv correspondingly has no Scimago Journal Rank (SJR) or quartile ranking.

    Search results that appear to show “bioRxiv” scientometric profiles, such as third-party aggregator pages listing publication and citation counts, are counting citations to the individual preprints hosted on the platform, not a journal-level metric assigned to bioRxiv itself. This distinction matters for anyone assessing where a piece of research sits in the scholarly record.

    ISSN record vs. Scimago-indexed journal
    Attribute bioRxiv (ISSN 2692-8205) Typical Scimago/Scopus-indexed journal
    Peer review before posting No — basic screening only Yes — mandatory
    ISSN Yes Yes
    Scopus/Scimago listing No Yes (if indexed)
    Impact factor / SJR None Assigned annually
    Editorial board with reject/accept decisions No Yes
    DOI registration Yes, via Crossref (prefix 10.1101) Yes, via Crossref or DataCite

    What does bioRxiv’s Wikipedia entry actually describe?

    The Wikipedia article for bioRxiv describes it plainly as “an open access preprint repository for the biological sciences”, founded by John Inglis and Richard Sever in November 2013 and inspired by arXiv, the physics and mathematics preprint server launched by Paul Ginsparg in 1991. The entry documents bioRxiv’s ownership history in detail: it was hosted by Cold Spring Harbor Laboratory (CSHL) until 11 March 2025, when ownership transferred to openRxiv, a newly formed nonprofit created to run bioRxiv and its clinical-sciences counterpart, medRxiv.

    Nowhere does the entry describe bioRxiv as a peer-reviewed journal. It explicitly notes that submissions “undergo a basic scrutinisation process, which includes safeguarding checks, an automated plagiarism screening and an assessment of appropriateness” — a moderation gate, not editorial peer review. The article also cites a 2019 eLife meta-research study (Abdill and Blekhman) finding that roughly two-thirds of bioRxiv preprints are subsequently published in peer-reviewed journals, underscoring that bioRxiv functions as a pre-publication staging ground rather than a publication venue in its own right.

    Is bioRxiv a journal, and what does “indexing” really mean?

    BioRxiv is not a journal. In scholarly-communication terms, “indexing” means a database such as Scopus, Web of Science, PubMed or the Directory of Open Access Journals has evaluated a title against inclusion criteria — regular publication schedule, peer review, editorial governance, ethical standards — and added its articles to a searchable, citation-tracked index. bioRxiv preprints are discoverable and citable via Google Scholar, PubMed Central (in some cases) and their own DOIs, but that is discovery, not journal indexing.

    • ISSN registration confirms serial identity only.
    • DOI registration (via Crossref) confirms a persistent, citable identifier for a specific preprint version.
    • Scopus/Web of Science indexing confirms a journal has passed a database’s editorial and peer-review vetting process.
    • Scimago/impact factor are journal-level citation metrics computed only for indexed journals — bioRxiv has neither.

    The bioRxiv-to-Journals (B2J) initiative, which by May 2020 allowed authors at 177 participating journals to submit a posted preprint directly into a journal’s manuscript system, illustrates the actual relationship: bioRxiv is a feeder and archive that sits upstream of formal, indexed publication, not a substitute for it. For definitions of related scholarly-communication terms, see the CASRAI Dictionary.

    Answer-first Q&A

    Does bioRxiv have an ISSN?

    Yes. BioRxiv holds ISSN 2692-8205, registered with the ISSN International Centre and cross-listed in the NLM Catalog (record 101680187). An ISSN is a serial-identification number confirming bioRxiv is a continuing publication series — it does not certify that content has passed peer review or editorial vetting.

    Is bioRxiv considered a journal?

    No. BioRxiv is a preprint repository, not a peer-reviewed journal. Submissions undergo only basic screening for plagiarism, safeguarding and appropriateness, not scientific peer review. A 2019 eLife study found roughly two-thirds of bioRxiv preprints are later published in peer-reviewed journals.

    Is bioRxiv a publisher?

    BioRxiv describes itself as an archive and distribution service, operated by the nonprofit openRxiv since March 2025 (previously hosted by Cold Spring Harbor Laboratory). It distributes manuscripts rather than publishing them editorially — authors remain free to submit the same work to a journal afterwards.

    How do you cite bioRxiv?

    Cite bioRxiv preprints using their DOI (prefix 10.1101, registered via Crossref), per bioRxiv’s own FAQ guidance. If multiple versions exist, cite the version-specific URL. ICMJE-aligned journals typically require the citation to flag the work explicitly as a preprint, unlike a peer-reviewed indexed article.

    What this means for authors and institutions

    For research administrators and institutional leaders verifying publication records, the practical takeaway is definitive: a bioRxiv deposit is not equivalent to a peer-reviewed, indexed publication for the purposes of research assessment exercises, promotion dossiers, or funder reporting, regardless of how citable or ISSN-bearing the platform is. Research administration teams verifying publication records for compliance purposes should treat a bioRxiv ISSN or DOI as evidence of deposit and discoverability, not as evidence of peer review or journal-level standing.

    Authors should continue citing bioRxiv preprints by DOI, clearly labelled as preprints, and should track whether a peer-reviewed version has since appeared in an indexed journal — since roughly two-thirds eventually do. Terminology precision matters here: conflating “has an ISSN” with “is indexed” or “is a journal” produces avoidable errors in CVs, grant reports and library catalogues. As preprint servers proliferate across disciplines, the ISSN-versus-indexing distinction bioRxiv illustrates will only become more relevant to how research administrators, publishers and funders classify the scholarly record.

  • Research Square vs bioRxiv: Ownership & Fees

    Research Square vs bioRxiv is, at its core, a nonprofit-versus-commercial question: Research Square is a preprint platform owned by the for-profit publisher Springer Nature, while bioRxiv and medRxiv are nonprofit servers now governed by openRxiv, an independent 501(c)(3) that took over from Cold Spring Harbor Laboratory (CSHL) in March 2025. Both are free for authors to use, but the ownership structure behind each one shapes fees, licensing control, data governance and long-term archival continuity in ways that matter for anyone advising authors on where to post.

    A preprint server is an online platform where researchers deposit manuscripts before, or independently of, formal peer review. Research Square, bioRxiv and medRxiv are three of the most widely used servers in the life, health and biomedical sciences, and authors are increasingly asked to choose between them without understanding what sits behind each brand.

    What Is the Core Difference Between Research Square and bioRxiv?

    The core difference is legal ownership and mission accountability, not scope or screening rigour. Research Square traces to American Journal Experts (AJE); Springer Nature took a minority stake in the Research Square platform in 2018, became majority owner in 2020, and completed full acquisition of Research Square Company in 2022. It is, today, a wholly commercial subsidiary of a for-profit publishing group.

    bioRxiv was founded in 2013 by John Inglis and Richard Sever at CSHL, a nonprofit research institution. medRxiv followed in 2019 as a partnership between CSHL, Yale University and BMJ. In March 2025, governance of both servers passed from CSHL to openRxiv, a newly formed independent nonprofit whose stated mission is “creating opportunities for sharing, discovering, and advancing preprints in the life and health sciences” — with a dedicated board and a Scientific and Medical Advisory Board of researchers overseeing policy.

    Feature Research Square bioRxiv / medRxiv (via openRxiv)
    Governing entity Springer Nature (for-profit publisher) openRxiv (independent nonprofit, 501(c)(3))
    Platform launched 2016, under Research Square Company bioRxiv 2013; medRxiv 2019
    Ownership shift Minority stake 2018 → majority 2020 → full acquisition 2022 Transitioned from CSHL to independent nonprofit, March 2025
    Author posting fee Free Free
    Sustainability model Cross-subsidised by Springer Nature publishing and AJE author-services revenue Philanthropic and institutional grants (Chan Zuckerberg Initiative, Sergey Brin Family Foundation, Robert Lourie Foundation, partner universities)
    Default licence CC-BY 4.0 required for all preprints Author’s choice: CC0, CC-BY, CC-BY-NC, CC-BY-ND, CC-BY-NC-ND, or no reuse without permission
    Journal integration In Review, tied to 1,000+ participating journals No equivalent journal-submission integration
    Bulk text-and-data-mining access No published bulk TDM programme; access via Crossref metadata and the site Monthly XML/PDF corpus via a requester-pays AWS S3 bucket, plus a public metadata API
    Long-term preservation Portico Portico

    Who Pays, and How Is Each Platform Funded?

    Neither model charges authors to post a preprint — that much is identical. What differs is where the money to run the platform comes from, and what that implies about future incentives. Research Square’s operating costs are absorbed by Springer Nature’s commercial publishing business and by AJE’s paid author-services division (editing, translation and related products), which Research Square continues to cross-sell alongside free preprint posting.

    openRxiv, by contrast, depends on renewable philanthropic and institutional grants rather than a parent company’s revenue. Its principal funders include the Chan Zuckerberg Initiative, the Sergey Brin Family Foundation, the Robert Lourie Foundation and a consortium of supporting universities including Caltech, MIT, Stanford, Yale and the University of Washington. That is a genuine trade-off, not a straightforward win for either side:

    • Research Square’s commercial backing gives it predictable, revenue-linked funding, but ties its long-term direction to Springer Nature’s corporate strategy.
    • openRxiv’s nonprofit funding is mission-locked by governance structure, but depends on grant renewal cycles rather than a guaranteed revenue stream.

    Who Owns and Controls Author Data?

    Ownership of the underlying manuscript stays with authors on both platforms — this is not a copyright grab by either side. The meaningful difference is licensing control and third-party data access. Research Square requires every posted preprint to carry a CC-BY 4.0 licence, which is the most permissive open licence and maximises reuse rights for readers, but leaves authors no choice in the matter.

    bioRxiv and medRxiv give authors a menu of licence options — CC0, CC-BY, CC-BY-NC, CC-BY-ND, CC-BY-NC-ND, or a “no reuse without permission” setting — and authors can change the licence on an existing preprint after posting. That is more author control, though funders that mandate CC-BY (a growing norm, including under several cOAlition S-aligned policies) require authors to actively select it rather than receiving it by default.

    The two models also diverge sharply on bulk data access. openRxiv publishes a full monthly XML/PDF text-and-data-mining corpus through a requester-pays AWS S3 bucket, alongside a public metadata API — an open-infrastructure commitment consistent with nonprofit, grant-funded governance. Research Square does not publish an equivalent bulk TDM feed; third-party discovery of Research Square content runs through Crossref DOI metadata and the platform’s own search interface rather than a dedicated open corpus.

    What Long-Term Archival Guarantees Does Each Model Offer?

    Both platforms use the same third-party preservation service: Portico provides perpetual-access archiving for preprints posted to Research Square, bioRxiv and medRxiv alike, so the archive itself is not where the two models diverge.

    The real difference is organisational continuity risk. A commercial platform’s archival commitments are ultimately corporate policy that could change with ownership or strategy; a nonprofit platform’s commitments are set by a mission-bound board, though it carries the separate risk of grant-funding renewal. Advising authors on a multi-decade preprint record means treating “who governs the archive” as distinct from “where is the archive stored.”

    Common Questions About Research Square and bioRxiv

    Is bioRxiv reputable?

    Yes. bioRxiv is widely cited across molecular and cell biology, screens submissions for plagiarism and non-scientific content, and is now governed by openRxiv, an independent nonprofit with a Scientific and Medical Advisory Board. Its reputation rests on community adoption and transparent, nonprofit governance rather than commercial incentives.

    Does bioRxiv count as published?

    No. A bioRxiv or medRxiv preprint is not peer-reviewed and does not constitute formal publication. The ICMJE treats preprints as legitimate scholarly communication, not duplicate publication, but funders and REF-style assessment exercises generally still require the peer-reviewed version for compliance credit.

    Is bioRxiv a preprint?

    bioRxiv is not itself a preprint — it is the server that hosts preprints. A preprint is the individual manuscript version posted before or independent of peer review; bioRxiv is the nonprofit infrastructure, now under openRxiv, that makes that posting possible for life-science research.

    What are the alternatives to bioRxiv?

    Alternatives include medRxiv for clinical and public-health research, Research Square for multidisciplinary and journal-integrated posting, and repository-style options such as arXiv, the Open Science Framework, Figshare and Zenodo. The right choice depends on discipline, human-subjects status and whether journal-integrated posting matters.

    What This Means for Authors and Research Administrators

    For most authors, the nonprofit-versus-commercial distinction will not change whether posting is free — it usually is, on both models. It should change how administrators frame the advice they give:

    • Explain that Research Square’s mandatory CC-BY licence maximises reuse but removes licensing choice, while bioRxiv/medRxiv give authors more control over which licence applies.
    • Flag that researchers doing large-scale corpus analysis will find far richer bulk access through openRxiv’s TDM feeds than through Research Square.
    • Note that archival preservation (Portico) is equivalent across models — the open question is who controls future platform policy, not the archive.
    • Treat commercial ownership as a disclosure point, not a disqualifier: Springer Nature’s backing gives Research Square’s In Review workflow journal-integration value a nonprofit model does not replicate.

    As more research administration offices build formal preprint guidance into their researcher-facing documentation, the originating business model behind a server deserves the same disclosure as its discipline coverage or screening depth. Authors are entitled to know not just where their manuscript will sit, but who ultimately governs the platform holding it — a nonprofit board answerable to a research mission, or a commercial parent answerable to shareholders.

    Last updated: 3 July 2026.

  • bioRxiv vs arXiv: Two Funding Models Compared

    bioRxiv vs arXiv is fundamentally a contrast in governance age and funding model: bioRxiv now operates under openRxiv, an independent nonprofit launched in March 2025 with a $16 million Chan Zuckerberg Initiative grant, while arXiv left Cornell University on 1 July 2026 to become arXiv, Inc., a member-governed Delaware nonprofit. Both are open-access preprint repositories, but the organisations behind them have chosen different paths to long-term sustainability.

    A preprint server is a repository that distributes complete but not-yet-peer-reviewed research manuscripts, allowing authors to establish priority and gather feedback before formal journal publication. The choice between bioRxiv and arXiv is usually made on subject scope — but the more consequential difference, and the subject of this analysis, is who pays for each server and who is accountable for keeping it running.

    What is the core difference between bioRxiv and arXiv?

    bioRxiv is a preprint repository for the life sciences, co-founded by John Inglis and Richard Sever in November 2013 and originally hosted at Cold Spring Harbor Laboratory (CSHL). arXiv is the older, broader repository, launched in 1991 by physicist Paul Ginsparg to serve physics, mathematics, computer science, quantitative biology, statistics and economics.

    The subject-matter split is well documented elsewhere. What is less widely reported is that both organisations have, within the past sixteen months, exited the institutions that originally housed them and adopted new independent governance structures — bioRxiv (with its clinical-sciences sibling medRxiv) in March 2025, and arXiv on 1 July 2026. That timing makes a direct governance comparison newly possible.

    Who funds and governs bioRxiv today?

    bioRxiv and medRxiv are now operated by openRxiv, an independent nonprofit that launched in March 2025 after both servers transferred out of Cold Spring Harbor Laboratory. The spin-out was funded by a $16 million grant from the Chan Zuckerberg Initiative (CZI), with additional foundational support from CSHL, BMJ Group and Yale School of Medicine.

    openRxiv runs a researcher-led governance board rather than a single-institution reporting line. Its board is chaired by Scott Fraser, CZI’s vice-president of science grant programmes, and includes medRxiv co-founder Harlan Krumholz (Yale cardiologist), Princeton University president emeritus Shirley Tilghman, and CSHL president Bruce Stillman. This puts editorial and operational oversight in the hands of named scientists rather than a university administration.

    The scale bioRxiv now supports is substantial: the server has posted roughly 268,000 preprints from around 970,000 authors, adding approximately 4,000 new submissions a month, while medRxiv has posted around 64,000 preprints and adds roughly 1,000 monthly. Authors cannot post the same manuscript to both servers — submissions must be routed to bioRxiv for basic biology or medRxiv for clinical and public-health work.

    How is arXiv’s new independent nonprofit structured?

    arXiv formally left Cornell University on 1 July 2026 to become arXiv, Inc., a standalone Delaware nonprofit corporation. Under Delaware nonprofit law, arXiv, Inc. was established by two founding Members — the Simons Foundation and Cornell University — who appointed the initial Board of Directors and secured the organisation’s IRS 501(c)(3) tax-exempt status.

    The Board of Directors will hold up to twelve seats, with Cornell and Simons Foundation serving as founding Members for up to five years before the seat structure opens further. arXiv, Inc. launched with three years of operating funding already secured, and Simons Foundation has committed support for at least five years.

    Unlike openRxiv’s grant-anchored model, arXiv layers a community membership programme on top of philanthropic funding: participating institutions pay up to $10,000 a year, scaled to the volume of preprints they post, in exchange for a formal voice in governance and access to usage data. Recent gift and grant activity illustrates the scale of philanthropic backing involved — arXiv received a combined $10 million from the Simons Foundation and the National Science Foundation in 2023, and a further $7 million from Schmidt Sciences and NASA in November 2025 to fund cloud migration and codebase modernisation, according to Cornell Chronicle and the arXiv blog.

    bioRxiv vs arXiv: governance and funding at a glance

    Feature bioRxiv (via openRxiv) arXiv (arXiv, Inc.)
    Founded November 2013 1991
    Field focus Life sciences (medRxiv covers clinical/health) Physics, mathematics, computer science, quantitative biology, economics
    Prior institutional host Cold Spring Harbor Laboratory, until March 2025 Cornell University, until 1 July 2026
    Current governing body openRxiv (independent nonprofit, launched March 2025) arXiv, Inc. (independent Delaware nonprofit, launched 1 July 2026)
    Governance structure Researcher-led board chaired by CZI’s Scott Fraser Up to 12-member Board of Directors; Simons Foundation and Cornell as founding Members
    Anchor funder / grant $16m Chan Zuckerberg Initiative grant (2025) $10m Simons Foundation/NSF (2023); $7m Schmidt Sciences/NASA (2025)
    Funding model Philanthropic grant-backed nonprofit Community membership fees (up to $10,000/institution) plus philanthropic grants
    Scale ~268,000 preprints, ~4,000 new/month 185,692 new submissions in 2022; 5m+ monthly active users

    What sustainability lessons does this hold for research infrastructure?

    Both transitions solve the same underlying problem — a critical piece of scholarly infrastructure had outgrown dependence on a single host institution’s budget and administrative structure — but they reach different equilibria. openRxiv concentrates funding risk in a small number of major philanthropic grants and a named scientific board; arXiv, Inc. spreads risk across founding-Member philanthropy, a rotating board, and a paying community membership base that also confers governance voice.

    For research-administration audiences, the comparison matters beyond preprints. Standards bodies, taxonomies and shared research infrastructure face the identical sustainability question: who pays when the founding host can no longer carry the cost, and who is accountable once it leaves? arXiv’s membership-fee model gives institutional funders a formal stake in governance decisions, which can improve long-term buy-in but adds administrative overhead; openRxiv’s grant-concentrated model is faster to stand up but leaves the organisation more exposed to a single funder’s priorities.

    • Diversified funding (multiple grants plus membership fees) tends to reduce single-point-of-failure risk, at the cost of governance complexity.
    • A named, credentialed scientific board — as both openRxiv and arXiv, Inc. now have — signals accountability to funders and the research community alike.
    • A founding-institution “off-ramp” clause (Cornell and Simons Foundation’s five-year Member term) gives a transition period without permanent institutional lock-in.

    Neither model has a multi-year track record yet: openRxiv is little more than a year old, and arXiv, Inc. has been operating for two days at the time of writing. The next eighteen to thirty-six months, as both organisations report their first independent financial results, will be the real test of which governance structure proves more resilient.

    Common questions about bioRxiv and arXiv

    Is arXiv the same as bioRxiv?

    No. arXiv and bioRxiv are separate organisations with different founding dates, subject scopes and governance structures. arXiv (1991) covers physics, mathematics and computer science and is now run by the independent nonprofit arXiv, Inc.; bioRxiv (2013) covers life sciences and is run by the separate nonprofit openRxiv.

    Who owns bioRxiv?

    bioRxiv has no single owner; it is operated by openRxiv, an independent 501(c)(3) nonprofit that launched in March 2025 after transferring from Cold Spring Harbor Laboratory. The transition was backed by a $16 million grant from the Chan Zuckerberg Initiative and governed by a researcher-led board.

    Is bioRxiv considered a publication?

    No. bioRxiv describes itself as a repository for preprints — complete but unpublished manuscripts that have not undergone peer review. Two-thirds of bioRxiv preprints are later published in peer-reviewed journals, but the preprint itself is not treated as the final scholarly record.

    Is arXiv a respected journal?

    arXiv is not a journal at all — it is a moderated preprint repository. Submissions are checked by volunteer moderators for scope and appropriateness but are not peer-reviewed in the journal sense, even though arXiv is widely regarded as authoritative within physics, mathematics and computer science.

    Both organisations illustrate that community-run research infrastructure now increasingly separates itself from any single host institution, replacing it with dedicated nonprofit governance and diversified funding. Institutions engaged in research administration evaluating which model to support — or which to emulate for other shared infrastructure — should watch how each organisation reports its first full year of independent finances.

  • openRxiv Explained: Why bioRxiv and medRxiv Went Independent

    openRxiv is the independent, researcher-led nonprofit that has run bioRxiv and medRxiv since March 2025, replacing Cold Spring Harbor Laboratory’s institutional stewardship with a six-member board, diversified funding, and a mandate to keep both preprint servers free to read and free to post. The spin-off was designed to insulate two of biomedicine’s most-used pieces of open-research infrastructure from dependence on any single institution or funder — a governance question every standards body and infrastructure provider eventually has to answer.

    openRxiv is the independent nonprofit, launched on 11 March 2025, that now stewards the bioRxiv and medRxiv preprint servers on behalf of the global research community, rather than as a programme of a single host institution.

    What is openRxiv, and what does it actually run?

    openRxiv is the organisational and legal home of two preprint servers: bioRxiv, covering life sciences, and medRxiv, covering health and clinical research. Neither server changed its submission process, screening policy, or URL when the transition happened — researchers post to biorxiv.org and medrxiv.org exactly as before.

    What changed is who is accountable for the platforms’ survival. bioRxiv was founded in 2013 at Cold Spring Harbor Laboratory (CSHL); medRxiv followed in 2019 as a joint initiative between CSHL, Yale University, and BMJ. Both grew into the dominant preprint venues for biomedicine, and by 2025 that success had outgrown the administrative capacity of a single laboratory to sustain indefinitely.

    Why did bioRxiv and medRxiv leave Cold Spring Harbor Laboratory?

    CSHL’s own account of the move calls it a “natural evolution,” not a rupture. Bruce Stillman, CSHL’s President and CEO, joined openRxiv’s board rather than severing ties, and co-founders John Inglis and Richard Sever moved with the platforms into the new entity.

    The stated rationale centres on three risks that concentrated stewardship inside one institution:

    • Sustainability risk — a single laboratory’s budget cycle is not designed to guarantee decades of continuity for global research infrastructure.
    • Governance risk — decisions about screening policy, features, and funding priorities benefited from a board drawn from outside CSHL alone.
    • Funder-concentration risk — the platforms needed a structure that could accept diversified funding without any one funder gaining outsized influence.

    openRxiv formally launched as an independent nonprofit on 11 March 2025, with the Chan Zuckerberg Initiative (CZI) providing three years of seed funding for the transition, according to openRxiv’s own governance Q&A published that May. In October 2025, arXiv — the physics, mathematics, and computer science preprint server run by Cornell University — joined openRxiv in submitting a joint response to a National Institutes of Health Request for Information on preprints, signalling a wider coalition forming around shared preprint-infrastructure interests, though arXiv itself remains a separate service.

    Who governs openRxiv, and who pays for it?

    openRxiv is governed by a six-member board of directors: Scott Fraser (University of Southern California and the CZI Imaging Institute), Edith Heard (Francis Crick Institute), Jeff Huber (Triatomic Capital), Harlan Krumholz (Yale School of Medicine; medRxiv co-founder), Bruce Stillman (CSHL), and Shirley Tilghman (Princeton University). A separate Scientific and Medical Advisory Board, chaired by John Inglis with medRxiv co-founder Theo Bloom as deputy, advises on content policy.

    The funding question is where most scrutiny has landed, given CZI’s long involvement with both servers before the spin-off:

    Question openRxiv’s public answer (governance Q&A, May 2025)
    How long has CZI funded the servers? Eight years for bioRxiv, four years for medRxiv, plus three years of dedicated seed funding for the openRxiv transition itself.
    Does CZI have editorial or operational control? No. openRxiv states funding agreements carry no stipulations affecting editorial or operational independence.
    How much board influence does CZI hold? One of six directors (Scott Fraser) has a CZI affiliation; the board is not CZI-appointed as a bloc.
    Is openRxiv against traditional peer review? No — openRxiv reports roughly 75% of bioRxiv and medRxiv preprints go on to formal peer-reviewed publication, with direct-submission links to 350 journals.

    openRxiv itself frames the governance model as a direct answer to funder-concentration concerns: the organisation states its mission is to be “governed by and for the research community, not a single funder, founder, or any one stakeholder.” Whether a philanthropic vehicle tied to a single tech-sector family remains structurally sufficient as the largest funder of a nonprofit intended to resist single-funder capture is a debate that predates this specific spin-off and will likely recur as openRxiv pursues its stated goal of diversifying revenue further.

    What is openRxiv Labs, and what launched in June 2026?

    openRxiv Labs launched on 1 June 2026 as a structured experimentation programme sitting on top of the core bioRxiv and medRxiv infrastructure. Rather than running many small tests at once, openRxiv committed to a small number of larger, hypothesis-driven pilots with predefined success metrics and durations, publishing results — including failures — openly on a dedicated Labs blog.

    The first Labs pilot, built with the platform Curvenote, tests an interactive preprint-reading interface layered onto openRxiv’s existing corpus of preprints, figures, and metadata. openRxiv named a broad partner list for the programme, including CZI, CSHL, the Sergey Brin Family Foundation, Caltech, CNRS, Fred Hutchinson Cancer Center, Imperial College London, MIT, Stanford, the University of Washington, and Vrije Universiteit Amsterdam — underscoring that the funder-diversification effort begun at launch has continued into 2026 rather than stalling after the initial CZI seed grant.

    Answer-first questions people are asking about openRxiv

    Who is the CEO of openRxiv?

    Dr Tracy Teal is openRxiv’s first Chief Executive Officer, appointed on 18 August 2025 after serving as interim COO since the March 2025 launch. She previously led The Carpentries and Dryad, two established open-research infrastructure nonprofits, giving her direct prior experience running community-governed scientific platforms.

    Who owns medRxiv?

    No single institution “owns” medRxiv today. It was founded in 2019 by Cold Spring Harbor Laboratory, Yale University, and BMJ, but operational and governance responsibility now sits with openRxiv, the independent nonprofit created specifically to steward it and bioRxiv without institutional or single-funder control.

    Is medRxiv a credible source?

    medRxiv preprints are screened but not peer-reviewed, so they should be cited with that caveat clearly stated. openRxiv reports around 75% of postings eventually complete formal peer review; until then, findings represent unverified claims from qualified researchers, useful for rapid awareness but not equivalent to a published, peer-reviewed article.

    What is openRxiv, in one line?

    openRxiv is the independent 501(c) nonprofit, launched 11 March 2025, that operates bioRxiv and medRxiv under a six-member board and a diversified-funding mandate, replacing their prior status as programmes hosted by Cold Spring Harbor Laboratory.

    What the openRxiv spin-off means for research-infrastructure stewardship

    The openRxiv case is a useful reference point for any organisation weighing how to govern shared research infrastructure once it outgrows its founding institution. The pattern — an originating body incubates a tool, the tool becomes essential community infrastructure, and stewardship then transfers to an independent, multi-stakeholder body — is not unique to preprints.

    CASRAI originated the CRediT contributor role taxonomy in 2014. The standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. That is the same “originator, not owner” pattern openRxiv is now navigating in public: CSHL originated bioRxiv and medRxiv, and stewardship has since passed to a body structured explicitly to prevent any one funder, founder, or institution from controlling research infrastructure the whole field depends on.

    For research administrators and institutional leaders, the practical takeaway is to watch governance structure, not just funding source, when assessing an infrastructure provider’s long-term reliability. A named, multi-institutional board; published funding-independence commitments; and open reporting of pilot outcomes (as with openRxiv Labs) are the concrete signals worth checking — independent of who wrote the first cheque.